FLCCC Statement on FDA’s Rollout of COVID-19 Vaccine Boosters
Published On: September 12, 2023|
By leveraging the unnecessary Emergency Use Authorization (EUA), the FDA is pushing forward with an experimental vaccine booster based on limited safety and efficacy data.
WASHINGTON, D.C. – The Food and Drug Administration has authorized and approved an updated mRNA vaccine for use in adults and children aged 6 months and up. This new shot targets the XBB.1.5 Omicron subvariant, which currently makes up only 3% of cases in the United States.
The circulating strains of the SARS Cov2 virus remain highly preventable and treatable with well-researched and proven effective therapies. The government’s ill-advised effort to encourage another vaccine booster lacks medical justification and erodes the public’s already waning trust in our public health authorities.
“The vaccine booster rollout is deeply flawed. We do not know enough about the COVID vaccines to make the broad recommendations that the FDA is making,” said Pierre Kory, MD, MPA, president and chief medical officer of the FLCCC. “There is so little data available on the safety of this latest booster, the FDA’s actions create an unnecessary risk to the public’s health, especially children and those who might still be suffering the life-altering side effects from previous COVID vaccinations and boosters.”
U.S. government’s Vaccine Adverse Events Reporting System shows that over 1.5 million adverse events associated with the vaccine have been reported since COVID-19 vaccinations became available to the public. According to the FDA’s own advisory, the latest booster underwent the minimal review and testing that is allowed under the current EUA.
“Our government continues to look for shortcuts in approving vaccines under the guise of an emergency while putting the public at risk of more injuries from these boosters that have not been through the extensive review and testing that is required outside of the EUA,” said Paul Marik, MD, chairman and chief scientific officer of the FLCCC. “I encourage our colleagues in the medical community to consider using other proven therapies that have little to no side effects before giving a patient an experimental vaccine that lacks the comparative safety and known efficacy.”
The FLCCC I-PREVENT COVID, FLU RSV, and I-CARE protocols effectively prevent and treat COVID-19 including the latest variants. Basing their recommendations on more than 300 published studies, the protocols were developed by a team of the world’s leading physicians and medical scientists to be used by the public in consultation with their healthcare provider to protect themselves from the COVID-19 virus.
In May 2022, the FLCCC released its protocol to treat those suffering from side effects from the COVID-19 vaccines, a condition identified as “Post-Vaccine Syndrome.” The protocol, called I-RECOVER: Post-Vaccine Treatment, uses a combination of FDA-approved medications and widely available supplements to treat the growing number of patients suffering from a broad range of symptoms following COVID-19 vaccination. More information about the I-RECOVER: Post-Vaccine Treatment protocol can be found here:
About the Front Line COVID-19 Critical Care Alliance
The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned critical care physicians and scholars with the academic support of allied physicians from around the world. FLCCC’s goal is to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness including the I-RECOVER protocols for “Long COVID” and Post Vaccine Syndrome. For more information: www.FLCCC.net